Medipost completes first dose of Cartistem in phase 3 clinical trials in Japan

South Korea's stem cell research company Medipost Co. said on Monday that it has completed the administration of Cartistem, a stem cell treatment fo...

Medipost's Cartistem shows effects on patellar cartilage defect patients

Medipost's knee osteoarthritis treatment Cartistem has been mentioned in a renowned international journal, showing that it is effective even in pati...